115478, Moscow, Kashirskoe highway 23

Unique Technologies Clinic «NeuroVita»

  • Ultra early molecular-biological diagnostics of the diseases of civilization
  • Innovation in neurology
  • Innovation in neurology
  • Ultra early molecular-biological diagnostics of the diseases of civilization
    Ultra early molecular-biological diagnostics of the diseases of civilization


  • Innovation in neurology
    Ultra early molecular-biological diagnostics of the diseases of civilization


  • Innovation in neurology
    Innovative approach to human longevity!


Unique Technologies

As we all know, the simplicity is the ultimate sophistication. Contemporary medicine understands simplicity as the perfection of the idea, the beauty of the concept, an out-of-the-box realization and a science-driven solution. Besides, to achieve a great scientific goal we need understanding of the fundamental aspects of the issue, adequate scope of the novel evidence, team of experts, appropriate equipment and a new hypothesis, which is not always simple. However, all prerequisites are available in the biotechnologies that have been developed by the NeuroVita Clinic.

Simplicity and ingenuity of the scientific idea of the Russian scientists lies in the fundamental research of one type of the cells, the hematopoietic stem cell of a human body that appears to contain the solution to the detection and treatment of the diseases of the civilization that accumulate in the body with the time due to the unfavorable environment long before manifestation of the clinical symptoms. The team of Prof. Bryukhovetskiy shows that the post-genomic (proteomic and transcriptomic) molecular-biological and cytofluorimetric analysis of the protein antigens of the membrane surface of the human HSCs permit detection of the fatal disease long before its clinical symptoms. Unique manipulations with the HSC and the chemical induction of the HSCs and their microenvironment permit obtaining the repaired, that is, healthy HSCs from autologous healthy somatic cells of the skin, fat, and/or muscles. The transfusion of the repaired HSCs promotes replacement of the damaged cells of the immune system with the healthy cells and permits avoiding most of the fatal disease of civilization and/or prevent their relapses.

          In the context of the proposed theory, Prof. Bryukhovetskiy and the team show that ageing of humans is conditioned by the disorders or damages of the molecular-biologic mechanisms of the systemic immune control and surveillance of the immune system and not by the exhaustion and age of the specialized cells of the tissues and organs. The disease-specific post-genome changes of the HSCs and the disorders of their regulatory function induce either the phenomenon of the hyporeactivity when the immune system does not detect the pathological cells as in cancer, or the phenomenon of the hyperreactivity when the immune system overreacts and destroys the specialized cells of the bodies and tissues as in the autoimmune and neurodegenerative diseases. These phenomena manifest in the changes of the proteomic structure of the HSCs and disease-specific proteins in it at the molecular-biological level leading to the loss of control over the injured cells and onset of the disease-specific immune insufficiency. The scientific discovery shows that immune insufficiency is different from the primary or secondary as it happens in the case of the AIDS or other infectious diseases, and, namely, qualitative genomic-protein and RNA degeneration of the immune-competent cells (ICCs) and HSCs while the quantity of the cells and their normal balance in the peripheral blood remain the same. This phenomenon is caused by the genomic and post-genomic (proteomic) damage of the HSC, the slowest cell of a human body, induced by the unfavorable effects of the environment like ionizing radiation, UHF, injuries, infections, intoxications or endogenous factors or endogenous factors like the carcinogens, local or systemic inflammation, ischemia and other.  

The genomic and post-genomic injury of the HSC at the level of the proteome, transcriptome, secretome and metabolome, in the bone marrow niches induces irreversible disorders of the protein structures of all progeny of the ICC of the blood, such as aseptic inflammation in the specialized cells, change of their phenotype and irreversible changes in the specialized tissues like degeneration and atrophy of the specialized cells or, on the contrary, their uncontrolled growth.

The cell cycle of the HSCs is 360 days, while all cells of the immune and hematopoietic systems are the progeny of the HSCs and live for 120 days. The post-genomic changes of the proteomic structure of the HSCs lead to long term inefficiency of the function of all progeny of the ICC in blood in a new generation.

The scientists of NeuroVita Clinic show that if the human body restores normal quantitative balance of the HSCs replacing them with the closely related precursors of the hematopoiesis or restoring their proteomic structure, it helps recover genetic and post-genomic mechanisms of the self-restoration of the human similar to that at a young age. It extends the active phase and life period at least by 30 to 40 years and even leads to the restoration of the reproductive function. Healthy HSCs are able to restore esthetic condition of the skin and somatic well-being of the organs and tissues, to normalize the internal state of the tissues and cell-tissular structure of the organs damaged by the environment.

The theory of Prof. Bryukhovetskiy provides an academic explanation for the longevity mentioned in the Bible that says that the patriarchs lived for about 1000 years. The mathematical models of the neurons provided by our mathematicians proved the biologic consistency of these data and showed that the neural cells of the humans are able to survive for over 1000 years and normal functioning of the HSC can provide for the regeneration of the organs and tissues.

In other words, Prof. Bryukhovetskiy presumes that ageing of the humans and almost all age-related diseases conditioned by the unfavorable environment are different types the proteomic disease of the main bioregulator of the human’s body, i.e. person’s own HSCs. The post-genomic (proteomic) damage of the HSC that was caused by the internal and external factors of the environment is the fundamental scientific reason of ageing and incurable age-related diseases.  In other words, the person dies from the disorder and damage of his basic regulatory systems of the restoration and reproduction of the damaged cells and loss of control after intratissular processes of self-restoration and hematopoiesis. The proteomic damage of the HSC by the negative environment and endogenous factors of homeostasis disorder is a universal tool of the evolution and natural selection given to the human by the creator (God, Nature, Evolution). A “sick mother” of all cells of the immune and hematopoietic systems (HSC) gives sick progeny, the billions of the cells that bear the disordered function of all immunocompetent cells, support the disease and promote its progress.  

Our scientists were the first in the world who established the fundamental universal mechanism of the proteomic damage of the HCS by the horizontal and vertical protein exchange through the microvesicular transport during the research. This mechanism explains for the reasons of not only the malignant disorders but also of the autoimmune and neurodegenerative diseases. The experiments of the Russian scientists in vivo and in vitro showed that the main age-related diseases of aggregation are the options of the post-genome disease of the human HSC, and not the diseases of the damaged specialized cells (neural, pancreatic, of connective tissue). The HSCs in the human body are the key tool of the recovery and regulation, so when we restore its molecular protein structure, we restore the natural biological basis of the self-management and self-regulation.

In the past five years, Prof. Andrey Bryukhovetskiy and his team made several discoveries in the post-genomic and regenerative medicine and made a breakthrough in the development of the unique post-genomic biotechnology of extremely early molecular-biological diagnostics of the range of the fatal diseases of civilization. The membrane protein of the HSC surface have been studied in 200 adult cancer cases and 250 children cancer cases and compared to the data of 52 healthy subjects. Mapping and profiling of the HSC membrane proteins helped detect disease-specific protein profiles on the HSC membrane surface. Thus, we are able to diagnose malignant disorders at a very early stage of disease when the tumor markers are not detectable and the molecular signs of degeneration and clinical symptoms are absent. Similar data have been received for the range of autoimmune and neurodegenerative disorders (Bryukhovetskiy AS, Grivtsova LY, 2019). The technology permits detection of various types of malignancies, autoimmune (such as type 1 diabetes, systemic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, autoimmune thyroiditis, polymyositis and other) and neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease, senile dementia, amyotrophic lateral sclerosis and other) at the earliest possible stage. Extremely early diagnostics permits detection of the disease in the bud, eliminate it and prevent its relapses (Bryukhovetskiy A.S.,2019). For the therapy we patented the biotechnology to develop a biomedical cell product from the line of the healthy stem cells obtained from the somatic cells through chemical induction. The preclinical trials extended the life period by 30% in laboratory animals and opened up the opportunity to extend the human life and to cure the so far incurable diseases. In the next two or three years the trials are planned to be accomplished and the method will become available for the patients.

The work of Professor Bryukhovetskiy and his team is at the frontiers of contemporary research. His works in the sphere of exosomal transport and immunotherapy of cancer are pioneering and ahead of the time.

Professor Bryukhovetskiy developed a new theoretical and methodological basis for the innovative neurotechnologies and original theory of the brain structure that was published in Russia and in the USA. The theory provides the foundation for the capitum-morphic nature-like super computer of a new generation, the neurobioprocessor based on the principles of holography and revolutionary neural interface. Relying on this theory, the group of Russian physicists and mathematicians headed by Dr. Brusilovskiy, a mathematician and radioengineer, discovered the microwave activity of the human brain in the range from 1 to 4 GHz (the patent application is filed). The range of encephalography varies from 1 to 7 Hz, while the discovered waves are one billion times different from any previously known activity of the human brain and belong to the ultra-high frequencies (UHF). Using the non reflecting room and the brand-new Rhode Schwartz (Germany) equipment for UHF the physicists and mathematicians detected the components of what was presumed to be thinking activity of the human brain. This opens up new opportunities to record the activity of the brain, define the information-commutation relations of different departments of the brain, and objectify visual and auditory hallucinations and structural disorders of thinking. Thinking was shown to be material, it can be registered and managed!

Other sphere of the research of Prof. Bryukhovetskiy is the development of the remote controlled contactless radioneuroengineering of the human brain that was patented in 2016 and introduced into clinical practice. The researchers integrated use of highly technological methods of electromagnetic effects involving low doses of ionizing radiation, focused ultrasound, structural-resonant therapy, extra high frequencies and the molecularly targeted drug and cellular therapy to restore the neural tissue of the brain and spinal cord. The achieved results can be compared to the open tissue engineering of the brain in large neurosurgical interventions or low-invasive radiosurgical interventions and functional neurosurgery. The technology was acknowledged by the Russian Patent Agency to be one of the top hundred inventions in 2017. The team of the scientists is ready to start implementing the idea of contactless reconstruction and biocontrol of the human brain in practice.

All biotechnologies of the team of Prof. Bryukhovetskiy are patented: 15 patents of the Russian Federation, 5 applications to the patents of the Russian Federation, 3 PCT applications for international patents and one US patent. In 2005 and 2006 the Clinic received official approval of the Russian Healthcare Surveillance Agency (Roszdravnadzor) for the clinical application of the technologies and they were included into the registry of new medical technologies (annulled in 2011) of the Ministry of Health. The developed technologies received positive feedback of Jack Welch, PhD, MD, from the US National Cancer Institute, Professor Mikhail I. Davydov, the academician of the Russian Academy of Science and the main oncologist of the country, Professor Vladimir G. Polyakov, academician of the Russian Academy of Science and the main children oncologist of the country, Professor Gennadiy T. Sukhikh and over 15 other top national experts. The research activity of the clinic was documented in 5 popular science films and over 60 popular science publications in mass media. Over 130 scientific articles have been published in the national and international journals, as well as 9 academic monographs and two-volume manual for doctors.

In a proactive manner privately sponsored Prof. Andrey S. Bryukhovetskiy and his team established a new biotechnological platform of the post-genome and regenerative medicine and developed ten unparalleled innovative biomedical technologies:

  1. The artificial neural tissue technology: 102 successful surgeries in tissue engineering of the human spinal cord to treat the consequences of the spinal cord injury including two cases of complete anatomical gap;
  2. The treatment of the organic damages of the brain and spinal cord with the peripheral blood mononuclear cells: 1 020 successfully treated severe neurological cases with organic damage of the brain who received totally over 18000 transfusions of the PBMCs products into the cerebrospinal fluid (CSF);
  3. The technology of the proteome-based cell therapy of cancer: 104 case of cancer have been successfully treated;
  4. The technology of the precision immunotherapy of cancer using proteomic anti-tumor dendritic vaccines and cytotoxic lymphocytes: 178 cancer cases;
  5. The technology of anti-cancer targeted cell preparations for lung and breast cancer and glioblastoma multiforme: 60 cancer cases,
  6. The technology of remote controlled multiwave contactless radioneuroengineering of the brain and spinal cord: 102 neurological patients in vegetative state and extremely severe brain injury;
  7. The technology of implanting the heterogeneous matrix “SpheroGel”©: over 360 patients with brain injury and damaged joints;
  8. The technology of anti-tumor exosomal-cellular products: 67 cases;
  9. The technology of anti-tumor artificial cellular-pharmaceutical immunity: 106 пациентов;
  10. The technology of the biomanagement of ageing and reproductive functions through infusion of the autologous PBMCs: 98 cases; used for anti-ageing and for esthetic correction of the age-related changes. The use of this autologous product every 6 months in mesotherapy of the face and neck provides for vigorous and long-term effect.

The innovations in biotechnologies are academic content and style of the work of NeuroVita Clinic in the past decades. The future and promise of these technologies is represented in the line of the biomedical cellular products (BMCP) for the treatment of severe neurological and cancer patients in Russia and abroad. The application for the inventions of the BMCP HemaComb, BMCP OncoComb, BMCP NeuroComb were filed in December, 2018.

  • Thank you for visiting our webpage!
  • Thank you for visiting our webpage!

    Thank you for visiting our webpage!

    Today cancer cannot be cured completely, but it can be transferred into a chronic and non-lethal disease, the survival rates can be significantly increased and the life quality can be improved. Alternatively, we can help provide a dignified departure from life, free from pain and humiliation.

    Sincerely yours, Professor, PhD, MD
    Andrey S. Bryukhovetskiy